ARROWHEAD PHARMACEUTICALS IN (ARWR)
US04280A1007 - Common Stock
ARROWHEAD PHARMACEUTICALS IN
NASDAQ:ARWR (11/26/2024, 6:22:33 PM)
After market: 21.6231 +0.57 (+2.72%)21.05
+2.26 (+12.03%)
Company Profile
Arrowhead Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development of medicines that treat intractable diseases by silencing the genes that cause them. The company is headquartered in Pasadena, California and currently employs 525 full-time employees. The firm's therapies, using a broad portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, trigger the RNA interference (RNAi) mechanism to induce rapid, deep and durable knockdown of target genes. The firm's Targeted RNAi Molecule (TRiMTM) platform utilizes ligand-mediated delivery and is designed to enable tissue-specific targeting while being structurally simple. The company is focused on various therapeutic areas, such as cardiometabolic, pulmonary, liver, muscle and central nervous system. The company has around 14 clinical-stage investigational medicines (nine wholly owned and five partnered), which range in development stage from Phase I to Phase III. The firm's pipeline products include Plozasiran, Zodasiran, Olpasiran, ARO-RAGE, ARO-MUC5AC, ARO-MMP7, GSK-4532990, Fazirsiran, JNJ-3989, HZN-457, ARO-C3, ARO-PNPLA3, ARO-DUX4 and ARO-SOD1.
Company Info
ARROWHEAD PHARMACEUTICALS IN
177 E Colorado Blvd, Suite 700
Pasadena CALIFORNIA 91105
P: 16266964702
CEO: Christopher Anzalone
Employees: 525
Website: https://arrowheadpharma.com/
ARWR News
3 hours ago - Arrowhead Pharmaceuticals, Inc.Arrowhead Pharmaceuticals Reports 2024 Fiscal Year-End Results
8 hours ago - ChartmillThe market is buzzing with gapping stocks on Tuesday. Let's uncover which stocks are experiencing notable gaps during today's session.Today's session on Tuesday is marked by notable gaps in various stocks. Stay informed with the gap up and gap down stocks in today's session.
10 hours ago - Investor's Business DailyArrowhead Launches 25% On A Massive Licensing Deal With SareptaThe deal focuses on four clinical-stage drugs, three preclinical assets and a potential five new targets.
10 hours ago - ChartmillWhich stocks are moving before the opening bell on Tuesday?Let's have a look at what is happening on the US markets before the opening bell on Tuesday. Below you can find the top gainers and losers in today's pre-market session.
12 hours ago - Arrowhead Pharmaceuticals, Inc.Arrowhead Pharmaceuticals Announces Global License and Collaboration Agreement with Sarepta Therapeutics for Multiple Clinical and Preclinical Programs8 days ago - Arrowhead Pharmaceuticals, Inc.Arrowhead Pharmaceuticals Submits New Drug Application to U.S. FDA for Plozasiran for the Treatment of Familial Chylomicronemia SyndromeARWR Twits
Here you can normally see the latest stock twits on ARWR, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits:
